DDInter385 DDInter1676
In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Cisapride {u} (Compound) resembles {v} (Compound) Metoclopramide
Cisapride {u} may lead to a major life threatening interaction when taken with {v} Iloperidone
Cisapride {u} (Compound) binds {v} (Gene) HTR2B
Cisapride {u} (Compound) upregulates {v} (Gene) PAK1
Cisapride {u} (Compound) downregulates {v} (Gene) PUF60
Cisapride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Cisapride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Morphine
Cisapride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nevirapine
Cisapride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Cisapride {u} may lead to a major life threatening interaction when taken with {v} Haloperidol
Cisapride (Compound) resembles Metoclopramide (Compound)
Cisapride may lead to a major life threatening interaction when taken with Iloperidone
Cisapride (Compound) binds HTR2B (Gene)
Cisapride (Compound) upregulates PAK1 (Gene)
Cisapride (Compound) downregulates PUF60 (Gene)
Cisapride may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Cisapride may cause a minor interaction that can limit clinical effects when taken with Morphine
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Nevirapine
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Cisapride may lead to a major life threatening interaction when taken with Haloperidol